Since November 2021, Omicron has emerged as the dominant severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) variant, and its sublineages continue to appear one …

Neutralizing antibodies (NAbs) are believed to be promising prophylactic and therapeutic
treatment against the coronavirus disease 2019 (COVID-19), which is caused by severe …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has precipitated multiple
variants resistant to therapeutic antibodies. In this study, 12 high-affinity antibodies were …

In this study, by characterizing several human monoclonal antibodies (mAbs) isolated from
single B cells of the COVID-19–recovered individuals in India who experienced ancestral …

The emergence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants
threatens efforts to contain the coronavirus disease 2019 (COVID-19) pandemic. Omicron …

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) initiates the infection
process by binding to the viral cellular receptor angiotensin-converting enzyme 2 through …

SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …

Background Neutralising antibodies against SARS-CoV-2 are a vital component in the fight
against COVID-19 pandemic, having the potential of both therapeutic and prophylactic …

The continuous emergence of novel SARS-CoV-2 variants poses new challenges to the fight
against the COVID-19 pandemic. The newly emerging Omicron strain caused serious …

Global concerns arose as the emerged and rapidly spreading SARS-CoV-2 variants might
escape host immunity induced by vaccination. In this study, a heterologous prime-boost …